<DOC>
	<DOCNO>NCT00760877</DOCNO>
	<brief_summary>The primary goal study determine rate confirm best cumulative complete molecular response ( CMR ) within first year study therapy imatinib nilotinib . The study also explore impact significance achieve CMR patient outcome ( progression free survival ( PFS ) , event free survival ( EFS ) overall survival ( OS ) , characterize kinetics CMR achieve treatment arm cross-over .</brief_summary>
	<brief_title>Nilotinib Versus Standard Imatinib ( 400/600 mg Every Day ( QD ) ) Comparing Kinetics Complete Molecular Response Chronic Myelogenous Leukemia Chronic Phase ( CML-CP ) Pts With Evidence Persistent Leukemia Real-time Quantitative Polymerase Chain Reaction ( RQ-PCR )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Diagnosis chronic myeloid leukemia associate BCRABL quantifiable RQPCR Documented CCyR bone marrow BCRABL &lt; 1 % IS past 12 month Persistent disease demonstrate two PCR positive test 3 month apart past 6 month . Treatment imatinib least 2 year 400 mg 600 mg stable dose No current plan antileukemia therapy Patient evidence rise PCR ( confirm &gt; 1 log increase previous 6 month ) Patient receive another investigational agent within last 6 month tyrosine kinase inhibitor ( TKIs ) imatinib Prior allogeneic stem cell transplantation Impaired cardiac function include one following : Inability monitor QT interval electrocardiogram ( ECG ) Long QT syndrome know family history long QT syndrome . Clinically significant rest brachycardia ( &lt; 50 beat per minute ) QTc &gt; 450 msec baseline ECG ( use QTcF formula ) . If QTcF &gt; 450 msec electrolyte within normal range , electrolyte correct patient rescreened QTc Myocardial infarction within 12 month prior start study Other clinically significant uncontrolled heart disease ( e.g . unstable angina , congestive heart failure uncontrolled hypertension ) History presence clinically significant ventricular atrial tachyarrhythmias Administration cytokine therapy ( e.g . GCSF , GMCSF SCF ) within 4 week prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>MYELOGENOUS</keyword>
	<keyword>LEUKEMIA</keyword>
	<keyword>Chronic Phase</keyword>
	<keyword>CML</keyword>
</DOC>